Financial Survey: Glucose Health (OTCMKTS:GLUC) and Exagen (NASDAQ:XGN)

Glucose Health (OTCMKTS:GLUC) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Glucose Health has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.

Insider and Institutional Ownership

75.3% of Exagen shares are held by institutional investors. 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Glucose Health and Exagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glucose Health	-108.70%	N/A	N/A
Exagen	-29.97%	-105.03%	-30.10%

Analyst Recommendations

This is a summary of recent ratings and price targets for Glucose Health and Exagen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glucose Health	0	0	0	0	0.00
Exagen	1	0	9	0	2.80

Exagen has a consensus price target of $9.57, indicating a potential upside of 243.06%. Given Exagen’s stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Glucose Health.

Valuation & Earnings

This table compares Glucose Health and Exagen”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glucose Health	$380,000.00	20.03	-$320,000.00	($0.03)	-12.41
Exagen	$66.57 million	1.01	-$19.95 million	($0.92)	-3.03

Glucose Health has higher earnings, but lower revenue than Exagen. Glucose Health is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Summary

Exagen beats Glucose Health on 9 of the 14 factors compared between the two stocks.

About Glucose Health

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.

About Exagen

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.